A NEW ERA IN MIGRAINE CARE: CLINICAL ADVANCES WITH RIMEGEPANT, UBROGEPANT, ATOGEPANT, AND ZAVEGEPANT – A NARRATIVE REVIEW
Abstract
Research objectives: To review and compare the mechanisms of action, clinical efficacy, safety, and unique clinical applications of four gepants - rimegepant, ubrogepant, atogepant, and zavegepant—in the management of migraine. To highlight the advantages of gepants over traditional migraine therapies, especially for patients with cardiovascular risks or medication overuse headache.
Methods: Narrative review synthesizing evidence from randomized controlled trials, observational studies, and meta-analyses. Literature search conducted via PubMed and Google Scholar, focusing on studies published between 2023 and 2025.
Key findings: Rimegepant is effective for both acute and preventive migraine treatment, with high patient satisfaction and a favorable safety profile. Ubrogepant is approved for acute treatment, showing efficacy particularly when administered early and in patients with cardiovascular contraindications. Atogepant is the first oral gepant approved specifically for migraine prevention, demonstrating significant reductions in monthly migraine days and acute medication use, even in patients unresponsive to other therapies. Zavegepant offers rapid relief via intranasal administration, making it suitable for patients with nausea or vomiting, though it has higher discontinuation rates compared to other gepants. All gepants exhibit generally mild and transient adverse events, with lower discontinuation rates than triptans.
Conclusions: Gepants represent a significant advancement in migraine management, providing effective and well-tolerated options for both acute and preventive treatment. Their distinct mechanisms and safety profiles allow for more personalized and safer migraine care, especially in populations unsuitable for older therapies. Future research should focus on direct comparative studies, long-term outcomes, and personalized treatment strategies to further optimize migraine management.
References
Ailani, J., Lipton, R. B., Blumenfeld, A. M., Mechtler, L., Klein, B. C., He, M. Y., Smith, J. H., Trugman, J. M., de Abreu Ferreira, R., & Brand-Schieber, E. (2025). Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study. Headache: The Journal of Head and Face Pain, 65(6), 1005. https://doi.org/10.1111/head.14871
Al-Hassany, L., Boucherie, D. M., Creeney, H., van Drie, R. W. A., Farham, F., Favaretto, S., Gollion, C., Grangeon, L., Lyons, H., Marschollek, K., Onan, D., Pensato, U., Stanyer, E., Waliszewska-Prosół, M., Wiels, W., Chen, H. Z., & Amin, F. M. (2023). Future targets for migraine treatment beyond CGRP. The Journal of Headache and Pain, 24(1), 76. https://doi.org/10.1186/s10194-023-01567-4
Alsaadi, T., Suliman, R., Yang, J., Agarwal, E., Fullerton, T., Chou, D. E., Whalen, E., El Jadam, C., Al Qaisi, I., Amin, Y., Alkhateri, A., Alsaffarini, K., Abraham, L., Zunaed, Z., Ahmed, H. M., Fathy, M., Hegab, M., & Vainstein, N. (2025). A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75 mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine. Cephalalgia: An International Journal of Headache, 45(7). https://doi.org/10.1177/03331024251355947
Aquipta : EPAR - Product Information (2025) Retrieved November 19, 2025 from https://www.ema.europa.eu/en/medicines/human/EPAR/aquipta
Begasse de Dhaem, O., Takizawa, T., & Dodick, D. W. (2023). Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks. https://journals.sagepub.com/doi/epub/10.1177/03331024221137092
Berman, G., Thiry, A., & Croop, R. (2024a). Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States. Journal of Pain Research, 1805. https://doi.org/10.2147/jpr.s453937
Berman, G., Thiry, A., & Croop, R. (2024b). Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States. Journal of Pain Research, 17, 1805. https://doi.org/10.2147/JPR.S453937
Biohaven Pharmaceuticals (2022). NURTEC ODT (Rimegepant) Orally Disintegrating Tablets, for Sublingual or Oral Use: US Prescribing Information. Retrieved November 19, 2025 from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ef08e09-1098-35cc-e053-2a95a90a3e1d&audience=professional; Kim et al., 2025
Biscetti, L., Cresta, E., Cupini, L. M., Calabresi, P., & Sarchielli, P. (2023). The putative role of neuroinflammation in the complex pathophysiology of migraine: From bench to bedside [Review of The putative role of neuroinflammation in the complex pathophysiology of migraine: From bench to bedside]. Neurobiology of Disease, 180, 106072. Elsevier BV. https://doi.org/10.1016/j.nbd.2023.106072
Brand-Schieber, E., Lipton, R., Blumenfeld, A., He, M. Y., Smith, J., Trugman, J., de Abreu Ferreira, R., & Ailani, J. (2024). Safety and Tolerability of Ubrogepant for the Acute Treatment of Migraine in Participants Taking Atogepant for the Preventive Treatment of Episodic Migraine: Results from the TANDEM Trial (S22.005). Neurology, 102. https://doi.org/10.1212/wnl.0000000000206434
Burch, R. C., Buse, D. C., & Lipton, R. B. (2018). Migraine Epidemiology, Burden, and Comorbidity. Neurologic Clinics, 37(4), 631. https://doi.org/10.1016/j.ncl.2019.06.001
Charles, A., & Brennan, K. C. (2009). Cortical Spreading Depression—New Insights and Persistent Questions. Cephalalgia, 29(10), 1115. https://doi.org/10.1111/j.1468-2982.2009.01983.x
Costa, C., Tozzi, A., Rainero, I., Cupini, L. M., Calabresi, P., Ayata, C., & Sarchielli, P. (2013). Cortical spreading depression as a target for anti-migraine agents [Review of Cortical spreading depression as a target for anti-migraine agents]. The Journal of Headache and Pain, 14(1). Springer Nature. https://doi.org/10.1186/1129-2377-14-62
Deeks, E. D. (2022). Atogepant: First Approval. Drugs, 82(1), 65. https://doi.org/10.1007/s40265-021-01644-5
Dhillon, S. (2023). Zavegepant: First Approval. Drugs, 83(9), 825. https://doi.org/10.1007/s40265-023-01885-6
Dodick, D. W. (2018). A Phase-by-Phase Review of Migraine Pathophysiology. Headache: The Journal of Head and Face Pain, 58, 4. https://doi.org/10.1111/head.13300
Dodick, D. W., Goadsby, P. J., Schwedt, T. J., Lipton, R. B., Liu, C., Lu, K., Yu, S. Y., Severt, L., Finnegan, M., & Trugman, J. M. (2023). Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. The Lancet, 402(10419), 2307. https://doi.org/10.1016/S0140-6736(23)01683-5
Durham, P. L. (2006). Calcitonin Gene‐Related Peptide (CGRP) and Migraine [Review of Calcitonin Gene‐Related Peptide (CGRP) and Migraine]. Headache The Journal of Head and Face Pain, 46. Wiley. https://doi.org/10.1111/j.1526-4610.2006.00483.x
Durham, P. L. (2008). Inhibition of Calcitonin Gene‐Related Peptide Function: A Promising Strategy for Treating Migraine [Review of Inhibition of Calcitonin Gene‐Related Peptide Function: A Promising Strategy for Treating Migraine]. Headache The Journal of Head and Face Pain, 48(8), 1269. Wiley. https://doi.org/10.1111/j.1526-4610.2008.01215.x
Durham, P. L., & Vause, C. V. (2010). Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists in the Treatment of Migraine. CNS Drugs, 24(7), 539. https://doi.org/10.2165/11534920-000000000-00000
Eltrafi, A., Shrestha, S., Ahmed, A., Mistry, H., Paudyal, V., & Khanal, S. (2023). Economic burden of chronic migraine in OECD countries: a systematic review [Review of Economic burden of chronic migraine in OECD countries: a systematic review]. Health Economics Review, 13(1). BioMed Central. https://doi.org/10.1186/s13561-023-00459-2
Erdener, Ş. E., Kaya, Ζ., & Dalkara, T. (2021). Parenchymal neuroinflammatory signaling and dural neurogenic inflammation in migraine [Review of Parenchymal neuroinflammatory signaling and dural neurogenic inflammation in migraine]. The Journal of Headache and Pain, 22(1). Springer Nature. https://doi.org/10.1186/s10194-021-01353-0
Goadsby, P. J., Jürgens, T. P., Brand-Schieber, E., Nagy, K., Liu, Y., Boinpally, R., Stodtmann, S., & Trugman, J. M. (2025). Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials. https://journals.sagepub.com/doi/epub/10.1177/03331024251320610
Headache Classification Committee of the International Headache Society (IHS). (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1. https://doi.org/10.1177/0333102417738202
Hou, M., Luo, X., He, S., Yang, X., Zhang, Q., Jin, M., Zhang, P., Li, Y., Bi, X., Li, J., Cheng, C., Xue, Q., Xing, H., & Liu, Y. (2024). Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis. The Journal of Headache and Pain, 25(1), 116. https://doi.org/10.1186/s10194-024-01822-2
Iannone, L. F., Vaghi, G., Sebastianelli, G., Casillo, F., Russo, A., Silvestro, M., Pistoia, F., Volta, G. D., Cortinovis, M., Chiarugi, A., Montisano, D. A., Prudenzano, M. P., Cevoli, S., Mampreso, E., Avino, G., Romozzi, M., Valente, M., Fasano, C., Battistini, S., … De Icco, R. (2025). Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). The Journal of Headache and Pain, 26(1), 4. https://doi.org/10.1186/s10194-024-01935-8
Johnston, K. M., Powell, L., Popoff, E., Harris, L., Croop, R., Coric, V., & L’Italien, G. (2022). Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm. The Clinical Journal of Pain, 38(11), 680. https://doi.org/10.1097/AJP.0000000000001072
Kim, G., Hoyt, M., Zakharyan, A., Durica, J., Wallem, A., & Viktrup, L. (2025). Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis. Advances in Therapy, 42(2), 918. https://doi.org/10.1007/s12325-024-03072-9
Kitamura, E., & Imai, N. (2024). Molecular and Cellular Neurobiology of Spreading Depolarization/Depression and Migraine: A Narrative Review [Review of Molecular and Cellular Neurobiology of Spreading Depolarization/Depression and Migraine: A Narrative Review]. International Journal of Molecular Sciences, 25(20), 11163. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/ijms252011163
Kitamura, S., Matsumori, Y., Yamamoto, T., Ishikawa, T., Hoshino, Y., Yoshimatsu, H., Thiry, A., Arakawa, A., Croop, R., Fullerton, T., Sakai, F., & Takeshima, T. (2025). Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-blind, randomized controlled trial. Headache: The Journal of Head and Face Pain, 65(8), 1403. https://doi.org/10.1111/head.14995
Kudrow, D., Hutchinson, S., Pixton, G. C., & Fullerton, T. (2024). Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study. Pain and Therapy. https://doi.org/10.1007/s40122-024-00675-6
Kurşun, O., Yemişçi, M., Maagdenberg, A. M. J. M. van den, & Karataş, H. (2021). Migraine and neuroinflammation: the inflammasome perspective [Review of Migraine and neuroinflammation: the inflammasome perspective]. The Journal of Headache and Pain, 22(1). Springer Nature. https://doi.org/10.1186/s10194-021-01271-1
Laohapiboolrattana, W., Jansem, P., Anukoolwittaya, P., Roongpiboonsopit, D., Hiransuthikul, A., Pongpitakmetha, T., Thanprasertsuk, S., & Rattanawong, W. (2024). Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis. The Journal of Headache and Pain, 25(1), 194. https://doi.org/10.1186/s10194-024-01904-1
Lauritzen, M., Dreier, J. P., Fabricius, M., Hartings, J. A., Graf, R., & Strong, A. J. (2010). Clinical Relevance of Cortical Spreading Depression in Neurological Disorders: Migraine, Malignant Stroke, Subarachnoid and Intracranial Hemorrhage, and Traumatic Brain Injury [Review of Clinical Relevance of Cortical Spreading Depression in Neurological Disorders: Migraine, Malignant Stroke, Subarachnoid and Intracranial Hemorrhage, and Traumatic Brain Injury]. Journal of Cerebral Blood Flow & Metabolism, 31(1), 17. SAGE Publishing. https://doi.org/10.1038/jcbfm.2010.191
Li, Y., Wang, X., Ballesteros-Perez, A., Bertz, R., & Lu, Z. (2023). Pharmacokinetics and Safety of Single and Multiple Daily Dosing of 75-mg Rimegepant Orally Disintegrating Tablets in Healthy Chinese Adults: A Randomized Placebo-Controlled Trial. Clinical Pharmacology in Drug Development, 12(6), 594. https://doi.org/10.1002/cpdd.1230
Lipton, R. B., Harriott, A. M., Julia, Y., Smith, J. H., Stokes, J., Gandhi, P., Jariwala‐Parikh, K., Jensen, G., Trugman, J. M., & Dodick, D. W. (2024). Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome. Neurology, 103(6). https://doi.org/10.1212/wnl.0000000000209745
Lipton, R. B., Lama, J. C., Serrano, D., Engstrom, E., Ayasse, N. D., Poh, W., Cadiou, F., & Adams, A. M. (2023). Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE. Neurology and Therapy, 13(1), 69. https://doi.org/10.1007/s40120-023-00556-8
Lipton, R., Kudrow, D., Smith, T., Ailani, J., Goadsby, P., Kamen, L., Thiry, A., Jensen, C., & Croop, R. (2023). Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Phase (P12-12.006). Neurology, 100. https://doi.org/10.1212/wnl.0000000000204207
Manack Adams, A., Hutchinson, S., Engstrom, E., Ayasse, N. D., Serrano, D., Davis, L., Sommer, K., Contreras-De Lama, J., & Lipton, R. B. (2023). Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study. The Journal of Headache and Pain, 24(1), 102. https://doi.org/10.1186/s10194-023-01622-0
Moore, E. L., Bell, I. M., Fraley, M. E., Burgey, C. S., White, R. B., Li, C., Regan, C. P., Danziger, A., McGaraughty, S., Kouzehgarani, G. N., Salvatore, C., & Banerjee, P. (2024). Pharmacologic characterization of atogepant: A potent and selective calcitonin gene–related peptide receptor antagonist. Cephalalgia, 44(1). https://doi.org/10.1177/03331024231226186
Morgan, C., & Nkadimeng, S. M. (2025). The Role of Inflammation in Migraine Headaches: A Review [Review of The Role of Inflammation in Migraine Headaches: A Review]. FASEB BioAdvances, 7(7). Wiley. https://doi.org/10.1096/fba.2024-00188
Mullin, K., Croop, R., Mosher, L., Fullerton, T., Madonia, J., & Lipton, R. B. (2024). Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study. Cephalalgia, 44(8). https://doi.org/10.1177/03331024241259456
National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 51049968, Rimegepant. Retrieved November 19, 2025 from https://pubchem.ncbi.nlm.nih.gov/compound/Rimegepant.
National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 53472683, Zavegepant. Retrieved November 19, 2025 from https://pubchem.ncbi.nlm.nih.gov/compound/Zavegepant.
National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 68748835, Ubrogepant. Retrieved November 19, 2025 from https://pubchem.ncbi.nlm.nih.gov/compound/Ubrogepant.
National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 72163100, Atogepant. Retrieved November 19, 2025 from https://pubchem.ncbi.nlm.nih.gov/compound/Atogepant.
Pellesi, L., Phu, T., Ernst, M., Hallas, J., & Pottegård, A. (2025). Adoption of rimegepant in Denmark: a register-based study on uptake, prescribing patterns and initiator characteristics. The Journal of Headache and Pain, 26(1). https://doi.org/10.1186/s10194-025-02028-w
Powell, L., O’Sullivan, F., Jayasinghe, P., Rogula, B., Dai, F., Cirillo, J., Sweeney, S., Abraham, L., & Ailani, J. (2025). Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial. The Journal of Headache and Pain, 26(1), 1. https://doi.org/10.1186/s10194-024-01915-y
Puledda, F., Silva, E. M., Suwanlaong, K., & Goadsby, P. J. (2023). Migraine: from pathophysiology to treatment. Journal of Neurology, 270(7), 3654. https://doi.org/10.1007/s00415-023-11706-1
Puledda, F., Younis, S., Huessler, E., Haghdoost, F., Lisicki, M., Goadsby, P. J., & Tassorelli, C. (2023). Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature [Review of Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature]. Cephalalgia, 43(3). SAGE Publishing. https://doi.org/10.1177/03331024231151419
Qin, R., & Barthold, D. (2025). EE301 Cost-effectiveness Analysis of Zavegepant in Acute Migraine Treatment. Value in Health, 28(6). https://doi.org/10.1016/j.jval.2025.04.2172
QULIPTA- atogepant tablet. Retrieved November 19, 2025 from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c8ab8f4-32bd-497a-befa-70c8a51d8d52)
Raggi, A., Leonardi, M., Arruda, M., Caponnetto, V., Castaldo, M., Coppola, G., Della Pietra, A., Fan, X., Garcia-Azorin, D., Gazerani, P., Grangeon, L., Grazzi, L., Hsiao, F.-J., Ihara, K., Labastida-Ramirez, A., Lange, K. S., Lisicki, M., Marcassoli, A., Montisano, D. A., … Martelletti, P. (2024). Hallmarks of primary headache: part 1 – migraine. The Journal of Headache and Pain, 25(1), 189. https://doi.org/10.1186/s10194-024-01889-x
Schwedt, T. J., Myers Oakes, T. M., Martinez, J. M., Vargas, B. B., Pandey, H., Pearlman, E. M., Richardson, D. R., Varnado, O. J., Cobas Meyer, M., & Goadsby, P. J. (2024). Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial. Neurology and Therapy, 13(1), 85. https://doi.org/10.1007/s40120-023-00562-w
Scott, L. J. (2020a). Ubrogepant: First Approval. Drugs, 80(3), 323. https://doi.org/10.1007/s40265-020-01264-5
Scott, L. J. (2020b). Rimegepant: First Approval. Drugs, 80(7), 741. https://doi.org/10.1007/s40265-020-01301-3
Shaukat, A., Shakeel, L., Riaz, R., Ashraf, S., & Akilimali, A. (2025). “The efficacy and safety of Atogepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials.” BMC Neurology, 25(1), 326. https://doi.org/10.1186/s12883-025-04350-x
Simmonds, L., Mehta, D., Cheema, S., Matharu, M., Swanson, J. W., & Matharu, M. (2023). Chapter 3 - Epidemiology of migraine (p. 31). Elsevier. https://www.sciencedirect.com/science/article/pii/B9780128233566000172
Song, Q., Gao, S., & Tan, Y. (2025). Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system. The Journal of Headache and Pain, 26(1), 147. https://doi.org/10.1186/s10194-025-02091-3
Song, Y., Zhao, S., Peng, P., Zhang, C., Liu, Y., Chen, Y., Luo, Y., Li, B., & Liu, L. (2024). Neuron-glia crosstalk and inflammatory mediators in migraine pathophysiology [Review of Neuron-glia crosstalk and inflammatory mediators in migraine pathophysiology]. Neuroscience, 560, 381. Elsevier BV. https://doi.org/10.1016/j.neuroscience.2024.10.006
Takano, T., & Nedergaard, M. (2008, December 18). Deciphering migraine. In Journal of Clinical Investigation. American Society for Clinical Investigation. https://doi.org/10.1172/jci38051
Tassorelli, C., Onishchenko, K., Halker Singh, R. B., Duan, M., Dupont-Benjamin, L., Hemstock, M., Voller, C., McAllister, P., Nahas, S. J., Gandhi, P., & Ailani, J. (2024). Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. Cephalalgia, 44(2). https://doi.org/10.1177/03331024241235156
True, D., Mullin, K., & Croop, R. (2024). Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study. Pain and Therapy, 13(5), 1203. https://doi.org/10.1007/s40122-024-00626-1
UBRELVY- ubrogepant tablet. Retrieved November 19, 2025 from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd9f9458-fd96-4688-be3f-f77b3d1af6ab
Vernieri, F., Iannone, L. F., Lo Castro, F., Sebastianelli, G., De Santis, F., Corrado, M., Marcosano, M., Ornello, R., Grazzi, L., Montisano, D. A., De Cesaris, F., Munafò, A., Fofi, L., Doretti, A., Vaghi, G., Pistoia, F., Ferrandi, D., Battistini, S., Sacco, S., … Altamura, C. (2025). Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study). Cephalalgia, 45(4). https://doi.org/10.1177/03331024251335927
Vitale, M. C., Tottene, A., Zadeh, M. Z., Brennan, K. C., & Pietrobon, D. (2023). Mechanisms of initiation of cortical spreading depression. The Journal of Headache and Pain, 24(1). https://doi.org/10.1186/s10194-023-01643-9
Vydura : EPAR - Product Information. (2025) Retrieved November 19, 2025 from https://www.ema.europa.eu/en/medicines/human/EPAR/vydura
Waliszewska-Prosół, M., Grandi, G., Ornello, R., Raffaelli, B., Straburzyński, M., Tana, C., & Martelletti, P. (2025). Menopause, Perimenopause, and Migraine: Understanding the Intersections and Implications for Treatment. Neurology and Therapy, 14(3), 665. https://doi.org/10.1007/s40120-025-00720-2
Waqas, M., Ansari, F. U. R., Nazir, A., Hussain, K. S. R., Sarfraz, Z., Sarfraz, A., Sarfraz, M., & Kc, M. (2023). Zavegepant nasal spray for the acute treatment of migraine: A meta analysis. Medicine, 102(43). https://doi.org/10.1097/MD.0000000000035632
Yang, C.-P., Liang, C., Chang, C., Yang, C.-C., Shih, P.-H., Yau, Y.-C., Tang, K., & Wang, S. (2021). Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine [Review of Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine]. JAMA Network Open, 4(10). American Medical Association. https://doi.org/10.1001/jamanetworkopen.2021.28544
ZAVZPRET- zavegepant spray. Retrieved November 19, 2025 from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c4a7aec-daef-4961-ba77-92f4b58be780.
Zhu, Z., Tang, Y., Li, L., Ni, H., Liu, M., Chen, Z., & Wang, Z. (2025). The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature. The Journal of Headache and Pain, 26(1), 48. https://doi.org/10.1186/s10194-025-01984-7
Copyright (c) 2025 Adam Januszkiewicz, Wiktoria Januszkiewicz, Wojciech Machulski, Martyna Ciarkowska, Michał Górski, Maria Gierasimiuk, Jan Makulski, Kamil Franczyk, Karolina Świerk, Damian Podkościelny
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
